Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-02-16

Opinion for Helius Medical Technologies (HSM-T)

Signal Price Bias Subject Owned
SPECULATIVE BUY $2.150 SELECTIVE NORTH AMERICAN Unknown

The odds for shareholders have improved.  They are in FDA trials.  They are speculative and make no money.  He likens it to a lottery ticket or better, to a raffle ticket as the odds are better. 

Fabrice Taylor
Publisher, The President's Club Newsletter

No Comments.


You must be logged in to comment.